HERCULES, CA — May 13, 2008 — Bio-Rad Laboratories, Inc. (AMEX: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostic products, today announced the new Bio-Rad CFX96™ real-time PCR detection system.
The CFX96 optical reaction module builds on the power and flexibility of the C1000 thermal cycler, creating an easy-to-install real-time PCR system that delivers sensitive, reliable detection for real-time PCR applications, including absolute quantification, genetic variation analysis, and gene expression. The flexible, easy-to-use CFX Manager™ software accommodates the needs of all users, whether performing a real-time PCR experiment or analyzing a comprehensive gene expression study.
Key benefits of the CFX96 system include:
- Long lasting solid-state components with LEDs and photodiodes for reliable results
- Quick installation and factory-calibrated optics, which enable system set-up in a matter of seconds
- Fast thermal cycling, which produces results in less than 30 minutes
- A thermal cycler gradient feature, which optimizes reactions in a single experiment
- Minimal sample and reagent usage that offer reliable results obtained with low reaction volumes
- Experiments that can be tailored to need by use one of several data acquisition modes, including a single channel fast scan option for SYBR® Green
- Software that can send email notification with an attached data file upon run completion and up to four instruments that may be controlled by a single computer
The CFX96 system offers users a way to achieve sensitive target detection in single (or multiplex assays) for a variety of real-time PCR applications in addition to reliable performance and higher throughput options. The CFX Manager software enables rapid quantitative and built-in gene expression analysis and also has powerful data analysis tools.
For more information visit https://www.bio-rad.com/realtime or call 1-800-876-3425 ext. 5638
Bio-Rad Laboratories, Inc. (AMEX: BIO and BIOb) has remained at the center of scientific discovery for more than 50 years manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 85,000 research and industry customers worldwide through its global network of operations. The company employs approximately 6,300 people globally and had revenues approaching $1.5 billion in 2007. For more information, visit www.bio-rad.com.
This release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "believe," "expect," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" in the Company's public reports filed with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2007, as updated by subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc. disclaims any obligation to update these forward-looking statements.